HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · Tesamorelin + Ipamorelin Blend (10mg / 5mg)
Growth-hormone-axis blend · research-use
A single-vial co-lyophilate of stabilized-GHRH tesamorelin and selective-secretagogue ipamorelin, batch-documented by HPLC and MS for research and private-label programs.
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Tesamorelin + Ipamorelin Blend (10mg / 5mg) |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 15mg |
| Documentation | Batch-document availability confirmed by product, specification and applicable lot |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized powder sealed at -20°C, protected from light and moisture; brief ambient transit is tolerated. After reconstitution, keep refrigerated at 2-8°C and use within the validated stability window. For laboratory research use only — not for consumer or veterinary use. |
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
A co-formulated research blend pairing tesamorelin, a 44-amino-acid DPP-IV-resistant analog of growth-hormone-releasing hormone (GHRH), with ipamorelin, a selective pentapeptide agonist of the ghrelin / growth-hormone-secretagogue (GHS) receptor. In research models the two components engage complementary nodes of the somatotropic axis — GHRH-receptor signaling and GHS-receptor signaling.
Documentation
batch-document availability confirmed by product, specification and applicable lot. Distribution scope confirmed before invoicing.
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Mass spectrometry identity confirmation against the Tesamorelin + Ipamorelin Blend (10mg / 5mg) reference profile.
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Each vial is co-lyophilized with 10 mg tesamorelin and 5 mg ipamorelin (15 mg total peptide) as a single mixed powder, not as two separate vials. The exact component identities and ratio are stated on the batch certificate of analysis.
No. A blend is a physical mixture, so it carries no single CAS number, molecular formula, or molecular weight. Documentation references each component's own identifiers instead: tesamorelin (CAS 218949-48-5, C221H366N72O67S, ~5135.9 g/mol) and ipamorelin (CAS 170851-70-4, C38H49N9O5, ~711.9 g/mol).
For the applicable lot, Pepti confirms whether available documentation includes a batch-linked certificate of analysis reporting HPLC purity and mass-spectrometry (MS) identity for both components. Additional third-party verification and testing (residual solvents, endotoxin (only if specifically ordered and tested), water content) can be arranged on request.
The standard format is a 15 mg vial (10 mg tesamorelin / 5 mg ipamorelin) at an MOQ of 50 kits (500 vials). Alternate ratios, fill weights, custom labeling, and private-label kitting are quoted on RFQ.
It ships as a sterile-filtered lyophilized powder under cold-chain, with COA and, where required, export documentation. Material is supplied for laboratory and manufacturing research use only; buyers are responsible for compliance with import and end-use regulations in their jurisdiction.
Related compounds
COA library search
The public COA library is being expanded by product and specification. Use the search link below to check current public records for this item.